A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study (Q93031588)
Jump to navigation
Jump to search
scientific article published on 01 September 2019
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study |
scientific article published on 01 September 2019 |
Statements
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study (English)
U Sahin
O Türeci
H Schulze-Bergkamen
Z Zvirbule
F Lordick
D Koeberle
P Thuss-Patience
T Ettrich
D Arnold
F Bassermann
S E Al-Batran
K Wiechen
K Dhaene
D Maurus
M Gold
C Huber
A Krivoshik
A Arozullah
J W Park